ZG005
Phase 2Biologic
ZG005 is one of 281 biologic programs targeting Lymphoma. It is currently in Phase 2.
10
Indications
14
Total Trials
12
Active Trials
280
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1SI-B001
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Standard Medical Therapy
PPost Graduate Institute of Medical Education and Research, Chandigarh
Phase 3
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
ZG005
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Hepatocellular Carcinoma2 trials
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Unknown status·—·N/A·NCT06233994·30 enrolled
Neuroendocrine Carcinoma2 trials
Lymphoma1 trial
6 more indications
Advanced Solid Tumor1 trial
Advanced Solid Tumors1 trial
Advanced Biliary Tract Carcinoma1 trial
Cervical Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZG005. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details